Investors

EISAI PRESENTS LATEST PHASE I/II DATA ON
IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011
RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITY
IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE

June 13, 2016

Eisai Co., Ltd. (“Eisai”) put out today the following press release about E6011, which Eisai has developed jointly with its gastrointestinal area subsidiary EA Pharma Co., Ltd.

EISAI PRESENTS LATEST PHASE I/II DATA ON
IN-HOUSE DEVELOPED ANTI-FRACTALKINE
ANTIBODY E6011

RESULTS SUGGEST SAFETY, TOLERABILITY AS
WELL AS CLINICAL ACTIVITY
IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE

For full text of the press release, please see the URL below in the website of Eisai Co., Ltd.
http://www.eisai.com/news/news201640.html

EA pharma Co., Ltd.
Corporate Planning Dept.

Back